Tissue-directed antibodies and methods of using the same
US-2024342260-A1 · Oct 17, 2024 · US
Methods for cancer therapy using isolated NTB-A ectodomain polypeptides
US11530251B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11530251-B2 |
| Application number | US-201916417048-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 20, 2019 |
| Priority date | Jan 9, 2014 |
| Publication date | Dec 20, 2022 |
| Grant date | Dec 20, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for preventing and treating cytopenia in susceptible patients, and for the ex vivo preparation of improved cell compositions.
First claim
Opening claim text (preview).
What is claimed: 1. A method of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an isolated NTB-A ectodomain, wherein said subject is afflicted with a tumor characterized by lack of NTB-A surface expression, wherein the isolated ectodomain lacks the signal peptide at positions 1-21 of NTB-A. 2. The method of claim 1 , comprising administering to said subject an isolated NTB-A ectodomain consisting of the IgV and IgC2 domains and lacking the signal peptide of NTB-A. 3. The method of claim 1 , wherein the NTB-A ectodomain is human NTB-A ectodomain. 4. The method of claim 1 , wherein the NTB-A ectodomain further comprises an epitope tag and/or a serum half-life elongating substance. 5. The method of claim 1 , wherein said subject is a cytopenic subject, or a subject at risk of developing cytopenia. 6. The method of claim 1 , wherein IL-2 is not exogenously administered to said subject. 7. The method of claim 1 , further comprising administering to said subject an extracellular portion of a CD137 ligand (CD137L) polypeptide, or an agonist antibody directed to CD137.
Assignees
Inventors
Classifications
- C07K14/70503Primary
Immunoglobulin superfamily · CPC title
comprising antibodies · CPC title
Antineoplastic agents · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
against the immunoglobulin superfamily · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11530251B2 cover?
- The present invention is directed to the field of immunotherapy. Specifically, the invention provides compositions and methods for improved T cell modulation ex vivo and in vivo and for the treatment of cancer and other pathologies. More specifically, embodiments of the invention are directed to the use of soluble NTB-A polypeptides or agonists thereof for the treatment of cancer patients, for …
- Who is the assignee on this patent?
- Hadasit Med Res Service
- What technology area does this patent fall under?
- Primary CPC classification C07K14/70503. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).